Specialty Pharmacy

Experts outline innovative approaches to reduce inequities in diagnostic access and optimize patient outcomes.

As psychedelic medicines near approval, pharmacists will become essential guides in safety and education.

From embedded PrEP care to rapid outbreak response logistics, new models are showing how pharmacists can establish successful public health partnerships to enhance patient access and equity.

Although long COVID remains a complex disease, pharmacists are critical team members for patient symptom validation, managing polypharmacy, and navigating therapy access.

An index of total cholesterol, high-density lipoprotein (HDL), and fasting glucose levels was found to indicate the prevalence of type 2 diabetes in a nationally representative US cohort.

The expanded indications now include adolescents with hidradenitis suppurativa aged 12 and older and pediatrics with uveitis aged 2 and older.

Ron Lanton outlines enforcement uncertainty and downstream effects on biosimilars, specialty drugs, and pharmacy supply chains under most favored nation pricing proposals.

These negative effects were primarily presented when cells were stressed by inflammatory proteins in patients with chronic kidney disease (CKD) with APOL1 mutations.

Steven Pipe, MD, highlights the growing importance of pharmacists in hemophilia care as new therapies expand treatment complexity and require specialized expertise.

The pharmaceutical giant will reportedly lower its drug prices to align with most-favored-nation status.

Ron Lanton advises pharmacies to maintain compliance, explore contingency options, and stay engaged with policymakers during the government shutdown.

A retrospective analysis found no associations between lipid parameters and the success of blood stem cell mobilization in a cohort of healthy donors.

Johnson & Johnson presented new long-term data of icotrokinra from ICONIC-LEAD, along with data from ICONIC-ADVANCE indicating head-to-head superiority with standard-of-care deucravacitinib.

The angiopoietin-like-3-targeting treatment received an expanded indication for individuals aged 1 through 5 years, building on earlier approvals in older populations.

In chronic kidney disease (CKD), SDMA showed a stronger connection to vascular health compared with ADMA.

The RNA interference therapy indicated that, along with its therapeutic benefits in cardiomyopathy transthyretin-mediated amyloidosis (ATTR-CM), there was a reduced risk of GI events.

In an announcement at the White House, Pfizer said it will reduce drug prices in the United States to match those of other countries.

AMT-130 demonstrates meaningful reductions in disease progression in the rare and chronic Huntington disease.

The new formulation of intravenous immunoglobulin (IVIG) provides patients another option to help reduce the incidence of severe bacterial infections.

A meta-analysis found that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors induce sustained reductions across lipid biomarkers, including low-density lipoprotein cholesterol (LDL-C).

The FDA linked cerebral folate deficiency to developmental delays with autistic features, although research remains ongoing.

The indication is for the treatment of adult and pediatric patients who weigh at least 30 kg.

Guselkumab becomes the first and only IL-23 inhibitor with a fully subcutaneous induction regimen for adults with ulcerative colitis.

Participating in a pharmacist-led secondary intervention clinic helped achieve large reductions in cholesterol levels among patients who have experienced an acute coronary syndrome.

Bumetanide nasal spray provides patients with edema an alternative to burdensome oral or intravenous diuretic options.

A series of PCSK9 inhibitors were found to be tolerable and effective at reducing low-density lipoprotein cholesterol in solid organ transplant recipients.

Investigators from the phase 3 COAST 1 trial demonstrated the efficacy and safety of amlitelimab in patients with moderate-to-severe atopic dermatitis.